Alpha Teknova, Inc.NASDAQ: TKNO

Teknova to Report Third Quarter 2026 Financial Results on November 4, 2026

· Issued by Alpha Teknova, Inc. via GlobeNewswire

Summary by 6ix AI

Alpha Teknova, Inc. (Teknova), a maker of reagents used in developing therapies, vaccines and molecular diagnostics, will report its financial results for the third quarter ended September 30, 2026, on Wednesday, November 4, 2026, after the market closes.

Key details

  • Teknova will host a webcast and conference call on Wednesday, November 4, 2026, beginning at 6:00 p.m. Eastern Time.
  • The live webcast can be accessed from the Investor Relations section of the Teknova website; participants who want to join the call must register for the webcast to receive a unique PIN number and dial-in information.
  • A replay will be available on the company's website approximately two hours after the event.

6ix AI wrote this summary from the release below and checked it against the release.

HOLLISTER, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2026, on Wednesday, November 4, 2026, following the close of market.

Teknova will host a webcast and conference call on Wednesday, November 4, 2026, beginning at 6:00 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to participate in the call, please register for the webcast here to receive a unique PIN number and dial-in information. The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Teknova
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in genomics, molecular diagnostics, and emerging therapeutic modalities. Our fast turnaround of high-quality agar plates, microbial culture and cryopreservation media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies.

Investor Contact
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100 

Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259

This press release was published by a CLEAR® Verified individual.


View original source (GlobeNewswire)Alpha Teknova, Inc. on 6ix

In the deck

Story so far

Earlier from Alpha Teknova

All Alpha Teknova news releases